The PD-1/PD-L1 pathway is an inhibitory immune checkpoint pathway that is upregulated within the tumor microenvironment [51, 52], and PD-1/PDL-1 checkpoint inhibitors are showing unprecedented clinical efficacy in certain cancer types, especially melanoma and lung [53]. Here, PDCD1 is linked to cancer.